ClinicalTrials.gg
CompletedNCT00073177Updated Oct 25, 2016

Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)

A Phase 3 interventional study of Roflumilast in Asthma, sponsored by AstraZeneca. Completed at 41 sites in 5 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-10-25.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
819
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing roflumilast in Asthma — none open to participants now, none under way, none of them phase 3. Roflumilast · Asthma.

Enrollment
3rd of 10
819 · median 300
Started
2003
with 2 others
Phase 3
5 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
8 of 10
AstraZeneca

Among the 10 studies testing roflumilast in Asthma, this one is the 3rd largest by enrollment, is one of 3 that started in 2003, is one of 5 in phase 3, and was the 1st registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 10 studies testing roflumilast in Asthma is open now. The open studies under Asthma, anywhere →

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing roflumilast in Asthma as a file.
02

Study summary

The aim of the study is to compare the effects of oral roflumilast with placebo on lung function in patients with asthma.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Persistent bronchial asthma
  • No change in asthma treatment within 4 weeks prior to visit 1
  • Non-smoker or ex-smoker (for 12 months or longer)

Main Exclusion Criteria:

  • Poorly controlled asthma or seasonal asthma
  • History of lower airway infection four weeks prior to visit 1
  • (COPD) and/or other relevant lung disease
  • Patients using > 8-puffs/day-short-acting bronchodilator (beta-agonists) (more than 3 days per week on average) prior to visit 1
  • abnormal laboratory values suggesting an undiagnosed disease, severe renal insufficiency, active hepatitis or an infection
  • Diagnosis, treatment or remission of any cancer (other than basal cell carcinoma) within two years prior to visit 1
  • Patients with chronic heart failure
  • Suspected and/or to roflumilast or albuterol/salbutamol
  • Female patients of not using adequate means of or pregnant or breast-feeding females
  • Patients who have received any medication or device in the month prior to visit 1 or who plan to use another investigational medication during the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
819 participants

Interventions

06

What researchers measure

Primary outcomes

  1. change in lung function from baseline to final visit.

Secondary outcomes

  1. pulmonary function variables

  2. diary variables

  3. quality of life variables

  4. time to first exacerbation

  5. number of asthma exacerbations

  6. safety.

07

Study locations

41 sites
  • ALTANA Pharma
    Cities in Alabama, Alabama, United States
  • ALTANA Pharma
    Cities in Arizona, Arizona, United States
  • ALTANA Pharma
    Cities in Arkansas, Arkansas, United States
  • ALTANA Pharma
    Cities in California, California, United States
  • ALTANA Pharma
    Cities in Colorado, Colorado, United States
  • ALTANA Pharma
    Cities in Florida, Florida, United States
  • ALTANA Pharma
    Cities in Georgia, Georgia, United States
  • ALTANA Pharma
    Cities in Idaho, Idaho, United States
  • ALTANA Pharma
    Cities in Illinois, Illinois, United States
  • ALTANA Pharma
    Cities in Indiana, Indiana, United States
  • ALTANA Pharma
    Cities in Iowa, Iowa, United States
  • ALTANA Pharma
    Cities in Kansas, Kansas, United States
  • ALTANA Pharma
    Cities in Kentucky, Kentucky, United States
  • ALTANA Pharma
    Cities in Louisiana, Louisiana, United States
  • ALTANA Pharma
    Cities in Maryland, Maryland, United States
  • ALTANA Pharma
    Massachusetts, Massachusetts, United States
  • ALTANA Pharma
    Cities in Michigan, Michigan, United States
  • ALTANA Pharma
    Cities in Minnesota, Minnesota, United States
  • ALTANA Pharma
    Cities in Mississippi, Mississippi, United States
  • ALTANA Pharma
    Cities in Missouri, Missouri, United States
  • ALTANA Pharma
    Cities in Montana, Montana, United States
  • ALTANA Pharma
    Cities in Nebraska, Nebraska, United States
  • ALTANA Pharma
    Cities in Nevada, Nevada, United States
  • ALTANA Pharma
    Cities in New Jersey, New Jersey, United States
  • ALTANA Pharma
    Cities in New York, New York, United States
  • ALTANA Pharma
    Cities in North Carolina, North Carolina, United States
  • ALTANA Pharma
    Cities in North Dakota, North Dakota, United States
  • ALTANA Pharma
    Cities in Oregon, Oregon, United States
  • ALTANA Pharma
    Cities in Pennsylvania, Pennsylvania, United States
  • ALTANA Pharma
    Cities in Rhode Island, Rhode Island, United States
  • ALTANA Pharma
    Cities in South Carolina, South Carolina, United States
  • ALTANA Pharma
    Cities in Tennessee, Tennessee, United States
  • ALTANA Pharma
    Cities in Texas, Texas, United States
  • ALTANA Pharma
    Cities in Utah, Utah, United States
  • ALTANA Pharma
    Cities in Virginia, Virginia, United States
  • ALTANA Pharma
    Cities in Washington, Washington, United States
  • ALTANA Pharma
    Cities in Wisconsin, Wisconsin, United States
  • ALTANA Pharma
    Cities in Argentina, Argentina
  • ALTANA Pharma
    Cities in Colombia, Colombia
  • ALTANA Pharma
    Cities in Mexico, Mexico
  • ALTANA Pharma
    Cities in Peru, Peru
08

References and documents

Publications

  • Chervinsky P, Meltzer EO, Busse W, Ohta K, Bardin P, Bredenbroker D, Bateman ED. Roflumilast for asthma: Safety findings from a pooled analysis of ten clinical studies. Pulm Pharmacol Ther. 2015 Dec;35 Suppl:S28-34. doi: 10.1016/j.pupt.2015.11.003. Epub 2015 Nov 22. PubMed 26612545 ↗
  • Meltzer EO, Chervinsky P, Busse W, Ohta K, Bardin P, Bredenbroker D, Bateman ED. Roflumilast for asthma: Efficacy findings in placebo-controlled studies. Pulm Pharmacol Ther. 2015 Dec;35 Suppl:S20-7. doi: 10.1016/j.pupt.2015.10.006. Epub 2015 Oct 21. PubMed 26498386 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00073177
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 19, 2003
Start date
Nov 2003
Last update
Oct 25, 2016

Study contacts

AstraZeneca AstraZeneca
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion